Research Analysts Set Expectations for HALO Q2 Earnings

Halozyme Therapeutics, Inc. (NASDAQ:HALO - Free Report) - Equities research analysts at Zacks Research increased their Q2 2025 earnings per share estimates for shares of Halozyme Therapeutics in a research note issued on Tuesday, March 11th. Zacks Research analyst R. Department now forecasts that the biopharmaceutical company will post earnings of $1.08 per share for the quarter, up from their previous forecast of $1.06. The consensus estimate for Halozyme Therapeutics' current full-year earnings is $4.73 per share. Zacks Research also issued estimates for Halozyme Therapeutics' Q3 2025 earnings at $1.31 EPS, Q4 2025 earnings at $1.58 EPS, FY2025 earnings at $4.86 EPS, Q1 2026 earnings at $1.28 EPS, Q2 2026 earnings at $1.41 EPS, Q3 2026 earnings at $1.57 EPS, Q4 2026 earnings at $1.71 EPS and FY2026 earnings at $5.96 EPS.

Several other research analysts have also commented on the company. HC Wainwright reiterated a "buy" rating on shares of Halozyme Therapeutics in a research report on Thursday, March 6th. Piper Sandler upped their price objective on Halozyme Therapeutics from $52.00 to $53.00 and gave the stock a "neutral" rating in a research note on Friday, January 10th. Benchmark restated a "buy" rating and set a $75.00 price objective on shares of Halozyme Therapeutics in a research note on Thursday, February 20th. Finally, Wells Fargo & Company lowered their price objective on Halozyme Therapeutics from $62.00 to $57.00 and set an "equal weight" rating for the company in a research note on Monday, January 13th. Four investment analysts have rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Moderate Buy" and an average price target of $62.78.

Remove Ads

Halozyme Therapeutics Stock Performance

Shares of HALO traded down $0.41 during mid-day trading on Friday, hitting $62.54. The stock had a trading volume of 1,226,195 shares, compared to its average volume of 1,310,033. The company has a market cap of $7.70 billion, a PE ratio of 18.23, a PEG ratio of 0.42 and a beta of 1.32. The company's fifty day simple moving average is $57.05 and its two-hundred day simple moving average is $54.63. The company has a quick ratio of 9.15, a current ratio of 7.80 and a debt-to-equity ratio of 4.14. Halozyme Therapeutics has a fifty-two week low of $37.73 and a fifty-two week high of $65.53.

Halozyme Therapeutics (NASDAQ:HALO - Get Free Report) last posted its quarterly earnings data on Tuesday, February 18th. The biopharmaceutical company reported $1.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.17 by $0.02. Halozyme Therapeutics had a return on equity of 157.78% and a net margin of 43.74%. The company had revenue of $298.01 million for the quarter, compared to the consensus estimate of $285.74 million.

Insiders Place Their Bets

In other Halozyme Therapeutics news, Director Jeffrey William Henderson sold 10,000 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $50.01, for a total value of $500,100.00. Following the transaction, the director now directly owns 43,611 shares of the company's stock, valued at $2,180,986.11. This represents a 18.65 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, SVP Michael J. Labarre sold 1,697 shares of the company's stock in a transaction dated Thursday, February 27th. The stock was sold at an average price of $58.28, for a total value of $98,901.16. Following the completion of the transaction, the senior vice president now directly owns 173,756 shares in the company, valued at approximately $10,126,499.68. The trade was a 0.97 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 31,697 shares of company stock valued at $1,754,451 in the last three months. Insiders own 2.40% of the company's stock.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the stock. CBIZ Investment Advisory Services LLC acquired a new position in shares of Halozyme Therapeutics during the 4th quarter valued at about $29,000. Heck Capital Advisors LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $29,000. Smartleaf Asset Management LLC grew its holdings in Halozyme Therapeutics by 29.2% in the 4th quarter. Smartleaf Asset Management LLC now owns 871 shares of the biopharmaceutical company's stock valued at $42,000 after buying an additional 197 shares during the last quarter. Venturi Wealth Management LLC acquired a new stake in Halozyme Therapeutics in the 4th quarter valued at approximately $69,000. Finally, Parkside Financial Bank & Trust grew its holdings in Halozyme Therapeutics by 21.8% in the 4th quarter. Parkside Financial Bank & Trust now owns 1,800 shares of the biopharmaceutical company's stock valued at $86,000 after buying an additional 322 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company's stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc, a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids.